| Literature DB >> 24028691 |
Maren Dreier1, Birgit Borutta, Gabriele Seidel, Inga Kreusel, Jürgen Töppich, Eva M Bitzer, Marie-Luise Dierks, Ulla Walter.
Abstract
BACKGROUND: Appropriate patient information materials may support the consumer's decision to attend or not to attend colorectal cancer (CRC) screening tests (fecal occult blood test and screening colonoscopy). The aim of this study was to develop a list of criteria to assess whether written health information materials on CRC screening provide balanced, unbiased, quantified, understandable, and evidence-based health information (EBHI) about CRC and CRC screening.Entities:
Mesh:
Year: 2013 PMID: 24028691 PMCID: PMC3848725 DOI: 10.1186/1471-2458-13-843
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Figure 1Study design used to develop the list of criteria and answer manual.
Content structure of the list of criteria for evaluating consumer information materials on colorectal cancer (CRC) screening (n = 230 criteria*)
| Information on CRC and CRC screening (32) | CRC screening (12) | Reported: yes / no | ||
| | | | Correct: yes / no / unclear | |
| | | | | Presentation format: text / number / chart / Table / figure |
| | | | | Evidence level reported: yes / no / lack of evidence indicated |
| | | | | Inclusion of quotes / notes |
| | | Information on screening colonoscopy (66) | Colonoscopy preparation (7) | Reported: yes / no |
| | | | Colonoscopy sedation (4) | Correct: yes / no / unclear |
| | | | Procedure (13) | Presentation format: text / number / chart / Table / figure |
| | | | Test characteristics (7) | |
| | | | Conduct in response to test results (3) | Evidence level reported: yes / no / lack of evidence indicated |
| | | | | |
| | | | | Inclusion of quotes / notes |
| | | | | |
| | | Information on FOBT (32) | Procedure (9) | Reported: yes / no |
| | | | Test characteristics (8) | Correct: yes / no / unclear |
| | | | Conduct in response to test results (3) | Presentation format: text / number / chart / Table / figure |
| | | | Benefit (disease-specific incidence and total mortality) (9) | |
| | | | | Evidence level reported: yes / no / indication of lack of evidence |
| | | | Risks and adverse effects including overdiagnosis (3) | |
| | | | | Inclusion of quotes / notes |
| Formal issues (33) | Author and stakeholders involved (14) | Reported: yes / no | ||
| | | | Editorial independence (6) | Inclusion of quotes / notes |
| | | | Sources and currentness of data (8) | |
| | | | Aim and target group (5) | |
| | Readability / comprehensibility (29) | Language (18) | Present: yes / mostly yes / mostly no / no / not applicable | |
| | | | | |
| | | | Content structure (3) | Inclusion of quotes / notes |
| | | | | |
| | | Layout (30) | Structure (11) | Present: yes / mostly yes / mostly no / no / not applicable |
| | | | Writing/font (6) | |
| | | | Inclusion of quotes / notes | |
| | | | Design (4) | |
| | Neutrality and balance (7) | Calls for participation (1) | Present: yes / no / unclear | |
| | | | Fear / downplay (4) | Inclusion of quotes / notes |
| Uneven presentation of procedures (2) |
The bold subtopics are presented in detail in Tables 2–5. The criteria of Domain D are listed in the text.
*One comprehensive criterion on the correctness of the information is not shown.
FOBT: fecal occult blood test.
Dimensions of the list of criteria (excerpt)
| Overall risk of adverse effects of screening colonoscopy is indicated | □ yes | □ yes | □ text | □ yes | |
| □ no | □ no | □ number | □ no | ||
| □ unclear | □ chart | □ lack of evidence indicated | |||
| □ table | |||||
| □ image | |||||
| Risk of pain is indicated | □ yes | □ yes | □ text | □ yes | |
| □ no | □ no | □ number | □ no | ||
| □ unclear | □ chart | □ lack of evidence indicated | |||
| □ table | |||||
| □ image | |||||
| Risk of cardiovascular symptoms is indicated | □ yes | □ yes | □ text | □ yes | |
| □ no | □ no | □ number | □ no | ||
| □ unclear | □ chart | □ lack of evidence indicated | |||
| □ table | |||||
| □ image | |||||
Criteria for sentences (n = 4), numerical data (n = 4) and visual elements (n = 9) (Domain C, sub topics from both categories)
| | | ||
| 1 | There is one message per sentence. | 1 | Visual elements are included. |
| 2 | Sentences are of appropriate length. | 2 | Drawings are used instead of photos. |
| 3 | Complex sentences are avoided. | 3 | Visual elements are explained in the text. |
| 4 | Identical repetitions are avoided. | 4 | The explanatory text is near the visual element. |
| | 5 | The visual element is not surrounded by text. | |
| 1 | Natural frequencies are used. | 6 | Visual elements are clearly labeled. |
| 2 | Reference parameters are given. | 7 | Biased scaling is avoided. |
| 3 | Same denominators are used. | 8 | Important spots of the visual element are marked by arrows, circles etc. |
| 4 | Loss and gain framing is balanced. | 9 | Visual elements include a legend. |
Criteria for the aetiology and epidemiology of CRC (n = 20) (Domain A, Category: Information on CRC and CRC screening)
| 1 | Meaning of premalignant conditions like polyps is stated. |
| 2 | Frequency of polyps/adenomas is stated. |
| 3 | Risk factors are stated. |
| 4 | Protective measures are stated. |
| 5 | Incidence is stated. |
| 6 | Sex-specific incidence is stated. |
| 7 | Age-specific incidence (age-stratified incidence) is stated. |
| 8 | Mortality is stated. |
| 9 | Sex-specific mortality is stated. |
| 10 | Age-specific mortality is stated. |
| 11 | Residual lifetime disease risk is stated. |
| 12 | Residual lifetime risk of death is stated. |
| 13 | Age-specific disease risk within a given time interval is stated. |
| 14 | Age-specific mortality risk within a given time interval is stated. |
| 15 | The disease risk compared to other cancer disease risks is stated. |
| 16 | The disease risk compared to other risks is stated. |
| 17 | The mortality risk compared to other cancer mortality risks is stated. |
| 18 | The mortality risk compared to other risks of death is stated. |
| 19 | The natural course of CRC is stated. |
| 20 | Incidence and mortality are not stated in one sentence. |
Criteria on benefits (n = 9) and risks (n = 23) of screening colonoscopy (Domain A, Category: Information on screening colonoscopy)
| Outcome: CRC incidence | |
| 1 | Absolute risk reduction is stated. |
| 2 | Relative risk reduction is stated. |
| 3 | Number needed to screen is stated. |
| Outcome: CRC mortality | |
| 4 | Absolute risk reduction is stated. |
| 5 | Relative risk reduction is stated. |
| 6 | Number needed to screen is stated. |
| Outcome: All cause mortality | |
| 7 | Absolute risk reduction is stated. |
| 8 | Relative risk reduction is stated. |
| 9 | Number needed to screen is stated. |
| Preparation | |
| 1 | Common risk of side effects is stated. |
| 2 | Risk of cardiovascular symptoms is stated. |
| 3 | Risk of nausea is stated. |
| 4 | Risk of allergies is stated. |
| 5 | Risk of cramps is stated. |
| 6 | Risk of pain is stated. |
| Sedation | |
| 7 | Common risk of side effects is stated. |
| 8 | Risk of respiratory distress/failure is stated. |
| 9 | Risk of cardiovascular symptoms is stated. |
| 10 | Risk of Nausea is stated. |
| Procedure itself | |
| 11 | Common risk of side effects is stated. |
| 12 | Number needed to harm is stated. |
| 13 | Risk of pain is stated. |
| 14 | Risk of cardiovascular symptoms is stated. |
| 15 | Risk of Nausea is stated. |
| 16 | Risk of bleeding is stated. |
| 17 | Risk of infection is stated. |
| 18 | Risk of perforation is stated. |
| 19 | Risk of mortality is stated. |
| Overdiagnosis | |
| 20 | Risk of overdiagnosis/overtreatment is stated. |
| 21 | Frequency of overdiagnosis is stated. |
| 23 | Consequences of overdiagnosis are stated. |
Figure 2Presentation of exemplary rating results of risks and adverse effects of screening colonoscopy in 13 brochures (11 criteria).